Literature DB >> 26820527

Role of protein kinase A and class II phosphatidylinositol 3-kinase C2β in the downregulation of KCa3.1 channel synthesis and membrane surface expression by lyso-globotriaosylceramide.

Ju Yeon Choi1, Seonghee Park2.   

Abstract

The intermediate conductance calcium-activated potassium channel (KCa3.1) mediates proliferation of many cell types including fibroblasts, and is a molecular target for intervention in various cell proliferative diseases. Our previous study showed that reduction of KCa3.1 channel expression by lyso-globotriaosylceramide (lyso-Gb3) inhibits differentiation into myofibroblasts and collagen synthesis, which might lead to development of ascending thoracic aortic aneurysm secondary to Fabry disease. However, how lyso-Gb3 downregulates KCa3.1 channel expression is unknown. Therefore, we aimed to investigate the underlying mechanisms of lyso-Gb3-mediated KCa3.1 channel downregulation, focusing on the cAMP signaling pathway. We found that lyso-Gb3 increased the intracellular cAMP concentration by upregulation of adenylyl cyclase 6 and inhibited ERK 1/2 phosphorylation through the protein kinase A (PKA) pathway, leading to the inhibition of KCa3.1 channel synthesis, not the exchange protein directly activated by cAMP (Epac) pathway. Moreover, lyso-Gb3 suppressed expression of class II phosphatidylinositol 3-kinase C2β (PI3KC2β) by PKA activation, which reduces the production of phosphatidylinositol 3-phosphate [PI(3)P], and the reduced membrane surface expression of KCa3.1 channel was recovered by increasing the intracellular levels of PI(3)P. Consequently, our findings that lyso-Gb3 inhibited both KCa3.1 channel synthesis and surface expression by increasing intracellular cAMP, and controlled surface expression through changes in PI3KC2β-mediated PI(3)P production, suggest that modulation of PKA and PI3KC2β activity to control of KCa3.1 channel expression can be an alternative important target to attenuate ascending thoracic aortic aneurysms in Fabry disease.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Class II phosphatidylinositol 3-kinase C2β; KCa3.1 channel; Lyso-globotriaosylceramide; Phosphatidylinositol 3-phosphate; Protein kinase A

Mesh:

Substances:

Year:  2016        PMID: 26820527     DOI: 10.1016/j.bbrc.2016.01.152

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Ion channels and pain in Fabry disease.

Authors:  Carina Weissmann; Adriana A Albanese; Natalia E Contreras; María N Gobetto; Libia C Salinas Castellanos; Osvaldo D Uchitel
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

2.  Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.

Authors:  Jarmila Lakomá; Roberto Rimondini; Antonio Ferrer Montiel; Vincenzo Donadio; Rocco Liguori; Marco Caprini
Journal:  Mol Pain       Date:  2016-08-16       Impact factor: 3.395

3.  Inhibition of Intermediate-Conductance Calcium-Activated K Channel (KCa3.1) and Fibroblast Mitogenesis by α-Linolenic Acid and Alterations of Channel Expression in the Lysosomal Storage Disorders, Fabry Disease, and Niemann Pick C.

Authors:  Aida Oliván-Viguera; Javier Lozano-Gerona; Laura López de Frutos; Jorge J Cebolla; Pilar Irún; Edgar Abarca-Lachen; Ana J García-Malinis; Ángel Luis García-Otín; Yolanda Gilaberte; Pilar Giraldo; Ralf Köhler
Journal:  Front Physiol       Date:  2017-01-31       Impact factor: 4.566

4.  Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?

Authors:  Verdiana Ravarotto; Gianni Carraro; Elisa Pagnin; Giovanni Bertoldi; Francesca Simioni; Giuseppe Maiolino; Matteo Martinato; Linda Landini; Paul A Davis; Lorenzo A Calò
Journal:  PLoS One       Date:  2018-09-27       Impact factor: 3.240

5.  The Effect of Green Tea as an Adjuvant to Enzyme Replacement Therapy on Oxidative Stress in Fabry Disease: A Pilot Study.

Authors:  Giovanni Bertoldi; Gianni Carraro; Verdiana Ravarotto; Valentina Di Vico; Paola Baldini Anastasio; Nicola Vitturi; Francesco Francini; Lucia Federica Stefanelli; Lorenzo A Calò
Journal:  Front Nutr       Date:  2022-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.